Research
Hormonal
87.3% of patients achieved weight loss of 5% or more after 6 months.
Practitioners can expect a high proportion of patients to achieve at least 5% weight loss with semaglutide.
StrongSupportsmedium confidence
Of the 102 patients who were followed up at 6 months, 89 (87.3%) achieved weight loss of 5% or more.
Why this rating
Based on the cohort study design and sample size.
Source
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Wissam Ghusn et al. · JAMA Network Open · 2022
DOI 10.1001/jamanetworkopen.2022.31982
cohort · n=408Cited 216×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →